Merck's Keytruda plus chemoradiotherapy to treat patients with FIGO 2014 Stage III-IVA cervical cancer receives US FDA approval

Merck, known as MSD outside of the United States and Canada, announced the US Food and Drug Administration (FDA) has approved Keytruda, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) [...]